Distribution of MED12 mutations in fibroadenomas and phyllodes tumors of the breast--implications for tumor biology and pathological diagnosis.
about
Phyllodes tumours of the breast: a consensus reviewExpression of EMT markers and mode of surgery are prognostic in phyllodes tumors of the breastMutational analysis of MED12 in fibroadenomas and phyllodes tumors of the breast by means of targeted next-generation sequencing.Myxoid fibroadenomas differ from conventional fibroadenomas: a hypothesis-generating study.Genetic alterations in uterine fibroids - a new direction for pharmacological intervention?Tubular, lactating, and ductal adenomas are devoid of MED12 Exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3K-AKT pathway.Phyllodes Tumor in a Lactating Breast.Genotyping of colorectal cancer for cancer precision medicine: Results from the IPH Center for Molecular Pathology.Mutations in genes encoding PI3K-AKT and MAPK signaling define anogenital papillary hidradenoma.MED12 is frequently mutated in breast phyllodes tumours: a study of 112 cases.Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy.Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity.Med12 regulates ovarian steroidogenesis, uterine development and maternal effects in the mammalian egg.MED12, TERT promoter and RBM15 mutations in primary and recurrent phyllodes tumours.MED12 protein expression in breast fibroepithelial lesions: correlation with mutation status and oestrogen receptor expression.MED12 exon 2 mutation as a highly sensitive and specific marker in distinguishing phyllodes tumours from other spindle neoplasms of the breast.Frequency of MED12 mutations in phyllodes tumors: Inverse correlation with histologic grade.Prospective single center trial of next-generation sequencing analysis in metastatic renal cell cancer: the MORE-TRIAL.
P2860
Q28079009-1B107714-FDC7-4A54-9C4E-CFBC444891A7Q33779480-E0896306-0910-4FB6-8BEF-37C83CB729DEQ35669552-466F427A-4BB8-4FD5-B72B-73F6A5F5163EQ36373960-93FC7148-9B8A-4856-A343-B9892CE2811CQ38570659-58D8BC24-ECD1-41B1-B220-DA13E5BC7BEBQ39580452-3869A3EB-9BCB-41B7-B25E-9C30936D8363Q39955897-CBFA864A-8591-41D6-B141-30A9BA4B2B05Q39967039-F7EE6417-DC8D-45BC-9A5F-5BD9A973306FQ40401895-B01046B9-1B81-49CD-9773-0AD013B833F2Q41712515-F57EF39E-F279-4721-ACAC-DA80170A29FAQ45901125-D9805FA1-5756-4704-8214-132F80B148D3Q46053202-7D80BB94-CBB4-40A0-8FDC-2A4CF9457CC3Q48508836-5662D4F4-9665-43D1-91DA-7CAC17C3FDA6Q50120771-8A68E1A1-1104-4641-9F4B-64492FB20F2DQ52876304-C4BDCB3D-CF75-4673-8E82-FD30D7BA2539Q53179448-14FFCB39-887A-4166-89D7-ADCC65EC06FFQ53267835-50051B7D-5625-45CD-B4E0-0C6531A194EAQ55040137-5685A5F6-2D68-41D1-9165-05CD52AF51F7
P2860
Distribution of MED12 mutations in fibroadenomas and phyllodes tumors of the breast--implications for tumor biology and pathological diagnosis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Distribution of MED12 mutation ...... gy and pathological diagnosis.
@en
Distribution of MED12 mutation ...... gy and pathological diagnosis.
@nl
type
label
Distribution of MED12 mutation ...... gy and pathological diagnosis.
@en
Distribution of MED12 mutation ...... gy and pathological diagnosis.
@nl
prefLabel
Distribution of MED12 mutation ...... gy and pathological diagnosis.
@en
Distribution of MED12 mutation ...... gy and pathological diagnosis.
@nl
P2093
P2860
P356
P1476
Distribution of MED12 mutation ...... gy and pathological diagnosis.
@en
P2093
Albrecht Stenzinger
Alexander Muckenhuber
Bernd Klosterhalfen
Esther Herpel
Frederick Klauschen
Jochen K Lennerz
Mark Kriegsmann
Moritz Jesinghaus
Nicole Pfarr
Roland Penzel
P2860
P304
P356
10.1002/GCC.22256
P50
P577
2015-04-30T00:00:00Z